Martin Mackay - 21 May 2025 Form 4 Insider Report for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)

Reporting relationship: Director
Issuer ticker: CRL
Reported as of: 21 May 2025
Net transaction value: +$517,918
SEC form: 4
Accepted by SEC: 23 May 2025, 16:19:56 UTC
Prior SEC filing: 15 May 2025
Next SEC filing: 02 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Martin Mackay

Key filing fact

Martin Mackay filed Form 4 for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) on 23 May 2025.

Key facts

This page summarizes Martin Mackay's Form 4 filing for CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 May 2025, 16:19.

Change

Previous filing in this sequence was filed on 15 May 2025.
Current net transaction value: +$517,918.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001414815 Primary reporting owner

MACKAY MARTIN

Relationship: Director
Address: C/O CHARLES RIVER LABORATORIES, 251 BALLARDVALE STREET, WILMINGTON
Signature: /s/ Martin Mackay
Signature date: 23 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRL transaction

Common Stock

Award

Transaction value: $127,691
Shares: +946
Change %: +7.5%
Price: $134.98
Shares after: 13,477
Date: 21 May 2025
Ownership: Direct
Footnotes: F1

CRL transaction

Common Stock

Award

Transaction value: $110,009
Shares: +815
Change %: +6%
Price: $134.98
Shares after: 14,292
Date: 21 May 2025
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRL transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $280,218
Shares: +2,076
Change %
Price: $134.98
Shares after: 2,076
Date: 21 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,076
Exercise price: $134.98
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The unvested restricted stock units vest upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders.

Footnote F2

The grant was made in lieu of director service fees for the term commencing May 20, 2025. The restricted stock units vest upon the earlier of 5/21/2026, or the business day prior to the Company's next annual meeting of shareholders.

Footnote F3

The stock options become exercisable upon the earlier of 5/21/2026 or the business day prior to the Company's next annual meeting of shareholders.